- Home
- ALXO vs SST Comparison
ALXO vs SST Comparison
Compare ALXO & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | SST |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | 300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.3M | 27.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALXO | SST |
|---|---|---|
| Price | $2.14 | $2.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 815.4K | 8.2K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.29 |
| 52 Week High | $2.66 | $11.30 |
Technical Indicators
Market Signals| Indicator | ALXO | SST |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 28.73 |
| Support Level | $2.01 | $0.34 |
| Resistance Level | $2.27 | $3.57 |
| Average True Range (ATR) | 0.20 | 0.25 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 19.53 | 15.68 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.